6 Green Days In A Row: Regeneron Pharmaceuticals Stock Is Up 13%
A multi-day run for the biotech stock has drawn attention, but the underlying numbers offer their own story.
Regeneron Pharmaceuticals (REGN) has now gained ground for 6 consecutive trading days. The stock’s cumulative gain over this period is 13.4%, a move that has added about $9.0 billion to its market value.
For investors holding the stock, this run has pushed the company’s valuation to about $76 billion.
The Streak Next To The S&P 500
- Amazon.com Stock Is Priced For The Bill, Not The Payback
- Meta’s Ad Growth Is Not The Number That Moved The Stock
- Altria Stock Trades Below The Market On Earnings And Above It On Sales
- UnitedHealth Stock Ran On A Repricing The Company Described In Advance
- Qualcomm Stock’s Biggest Risk Is The Gap Between Pain And Payoff
- The Signs Before Eli Lilly Stock Surged Were All On The Record
Here is how REGN stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | REGN | S&P 500 |
|---|---|---|
| 1D | 6.2% | 1.7% |
| 6D (Current Streak) | 13.4% | -0.8% |
| 1M (21D) | 18.4% | -0.8% |
| 3M (63D) | 7.7% | 4.2% |
| YTD 2026 | -4.1% | 8.6% |
| 2025 | 9.0% | 16.4% |
| 2024 | -18.9% | 23.3% |
| 2023 | 21.7% | 24.2% |
What is fueling the run?
While the streak began before, what really fueled the total return was Regeneron’s Q2 2026 results, released on July 30.
In addition, the company’s recent performance metrics stand out against market medians. Revenue over the last twelve months grew 9.3%, ahead of the S&P 500 median of 7.8%. Its operating margin is 26.9%, compared to the S&P 500 median of 18.4%. While the stock has moved higher, it trades at a price-to-earnings multiple of 17.5, below the S&P 500 median of 24.0.
This streak is also specific to the stock, as over the same 6 trading days the S&P 500 returned -0.8%. For context, just 21 S&P 500 stocks are currently on winning streaks of 3 days or more.
A streak is a signal, not a strategy.
A run of this length is information. It signals that the market is paying attention and that momentum is a factor. But streaks end, often without warning. The disciplined response is not to chase the chart, but to use the new price as a prompt to re-evaluate the business.
The data on growth, margins, and valuation relative to the market provides a starting point for that assessment.
If you are hunting for strength that has more behind it than a hot tape, our Guidance Momentum screen surfaces the names where management raised its own outlook, which is the kind of momentum that tends to persist.
Prefer the theme to this single name? A biotech ETF like IBB owns the whole group. That way no single company’s next surprise decides the outcome.
Winning Streaks Are How Portfolios Get Concentrated
A stock that rises day after day quietly becomes a bigger share of the portfolio holding it. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.